Erythropoietic protoporphyria with liver cirrhosis as the main manifestation： A case report / 临床肝胆病杂志

Erythropoietic protoporphyria （EPP） is a rare inherited metabolic disease that often involves skin， blood， and nervous systems， and EPP with the main manifestations of severe liver damage and acute abdominal pain is extremely rare. By reviewing the clinical data and genetic testing results of a patient with EPP， this article discusses the clinical features and pathogenic genes of this disease， in order to improve the understanding of the disease among hepatologists and achieve early diagnosis and treatment.

Bullous lesions following phototherapy in a newborn

ABSTRACT A male infant presented with progressive jaundice immediately after birth. Fecal acholia and choluria associated with extensive bullous skin lesions in his trunk, abdomen, and upper and lower limbs developed during phototherapy. Several diagnostic hypotheses were presented, including neonatal porphyria, hemochromatosis, Alagille syndrome, and neonatal lupus. A 24-hour urine sample for the dosage of urinary porphyrins was collected, showing high results (1823.6µg in 100mL). At 50 days of life, fluorescence spectroscopy using a Wood's lamp revealed simultaneous bright red fluorescence of urine-stained diapers and sample blood. A definitive diagnosis of congenital erythropoietic porphyria was made following identification of a mutation of the uroporphyrinogen synthetases III gene on genetic testing. The patient was subsequently maintained in a low light environment since then, resulting in improvement of the lesions. Congenital erythropoietic porphyria is a disease of the group of porphyrias that presents shortly after birth with blistering occurring in regions exposed to the sun or other ultraviolet light. Atrophic scars, mutilated fingers, and bright red fluorescence of the urine and teeth may also be observed. There is no specific treatment, and prophylaxis comprising a total avoidance of sunlight is generally recommended. A high degree of suspicion is required for diagnosis. An early diagnosis can lead to less damage. Here, we present the case of a newborn with congenital erythropoietic porphyria diagnosed after presenting with bullous lesions secondary to phototherapy.

Porfiria hepato eritropoyética asociada a diabetes mellitus tipo 1: a propósito de un caso clínico / A clinical case of hepato-erythropoietic porphyria associated with type 1 diabetes mellitus / Relato de caso de porfiria hepato-eritropoiética associada a diabetes mellitus tipo 1

Las porfirias son un grupo complejo y heterogéneo de defectos en la vía de la síntesis del hemo. La porfiria hepato eritropoyética es un subtipo muy poco frecuente y de presentación en la infancia, con compromiso cutáneo predominante. Describimos el caso clínico de una paciente de 5 años, que se presenta con lesiones cutáneas e hipertricosis, se confirma el diagnóstico por elevación de uroporfirinas en orina y secuenciación del gen UROD.

Porphyria is a complex and heterogeneous group of heme synthesis disorder. Hepato-erythropoietic porphyria is a very rare subtype that onsets in childhood, and shows predominant skin involvement. We describe the clinical case of a 5-year-old patient who showed skin lesions and hypertrichosis and whose diagnosis was confirmed due to increased uroporphyrins in urine and UROD gene sequencing

A porfiria é um grupo complexo e heterogêneo de distúrbios da síntese do grupo heme. A porfiria hepato-eritropoiética é um subtipo muito raro que se inicia na infância e mostra envolvimento predominante da pele. Descrevemos o caso clínico de uma paciente de 5 anos que apresentou lesões cutâneas e hipertricose e cujo diagnóstico foi confirmado por aumento de uroporfirinas na urina e sequenciamento do gene UROD.

Dolor abdominal y parálisis flácida, una aproximación a las porfirias: serie de casos y revisión de la literatura / Flaccid paralysis and abdominal pain, an approach to porphyrias: a literature review and case series

RESUMEN Las porfirias son trastornos metabólicos hereditarios causados por deficiencias enzimáticas de la biosíntesis del grupo HEM. Con presentación en distintos grupos de edades, más común en infancia y tercera a cuarta década de la vida, se caracterizan por elevación de porfirinas, y manifestaciones variadas cutáneas y neuro viscerales. Describimos una serie de 3 casos de pacientes femeninas en tercera década de la vida con dolor abdominal severo e inespecífico y una amplia gama de manifestaciones clínicas con sus complicaciones a corto y largo plazo en quienes se diagnosticó porfiria aguda intermitente (PAI). Se hará revisión en la literatura para aportar al reconocimiento temprano de estas condiciones e instaurar de forma temprana el manejo específico e impactar en desenlaces irreversibles.

ABSTRACT Porphyrias are inherited metabolic disorders caused by enzymatic deficiencies of HEM group biosynthesis. Most common in childhood at the third and fourth decade of life. They are characterized by increased levels of porphyrins, and various cutaneous, neurological, and visceral manifestations. We describe a series of 3 cases of female patients in the third decade of life with abdominal pain and a wide range of clinical manifestations and short and long-term complications. Our review contributes to the early recognition of these diseases to establish early specific managements to impact on irreversible outcomes.

Ocular manifestations in patient with congenital erythropoietic porphyria

We present the case of a 52-year-old woman referred to our service because of extreme ocular surface dryness. The patient showed corneal, conjunctival, and eyelid manifestations of ocular congenital erythropoietic porphyria (CEP). We started treatment with autologous serum, topical steroids, and cyclosporine twice a day, topical retinoids, and intense corneal lubrication. The patient referred significant improvement of ocular bothering and less discomfort since treatment was initiated. We describe the management of the herewith presented case of ocular CEP.

The role of ClpX in erythropoietic protoporphyria

ABSTRACT Hemoglobin is an essential biological component of human physiology and its production in red blood cells relies upon proper biosynthesis of heme and globin protein. Disruption in the synthesis of these precursors accounts for a number of human blood disorders found in patients. Mutations in genes encoding heme biosynthesis enzymes are associated with a broad class of metabolic disorders called porphyrias. In particular, one subtype - erythropoietic protoporphyria - is caused by the accumulation of protoporphyrin IX. Erythropoietic protoporphyria patients suffer from photosensitivity and a higher risk of liver failure, which is the principle cause of morbidity and mortality. Approximately 90% of these patients carry loss-of-function mutations in the enzyme ferrochelatase (FECH), while 5% of cases are associated with activating mutations in the C-terminus of ALAS2. Recent work has begun to uncover novel mechanisms of heme regulation that may account for the remaining 5% of cases with previously unknown genetic basis. One erythropoietic protoporphyria family has been identified with inherited mutations in the AAA+ protease ClpXP that regulates ALAS activity. In this review article, recent findings on the role of ClpXP as both an activating unfoldase and degrading protease and its impact on heme synthesis will be discussed. This review will also highlight the role of ClpX dysfunction in erythropoietic protoporphyria.

Porfiria eritropoyética congénita: reporte de un caso y recomendaciones de manejo / Congenital erythropoietic porphyria: case report and management recommendations

La porfiria eritropoyética congènita es una porfiria cutánea no aguda, extremadamente poco frecuente, autosómica recesiva, producida por la deficiencia de la enzima uroporfirinógeno III sintetasa codificada en el gen UROS, en el cromosoma 10q26.2. Esto genera el depósito y la acumulación de porfirinas en las córneas, los huesos y los dientes. Se presenta desde los primeros meses de vida con intensa fotosensibilidad, que se manifiesta con fragilidad cutánea con formación de vesículas, bulas y costras. El curso grave lleva a la mutilación de tejidos acrales, compromiso ocular, anemia hemolítica e hiperesplenismo. El manejo es complejo, basado, sobre todo, en la fotoprotección. Un correcto diagnóstico y enfrentamiento puede mejorar notablemente la calidad y expectativas de vida de estos pacientes. Se presenta el caso de un lactante con porfiria eritropoyética congénita confirmada con el estudio genético.

Congenital erythropoietic porphyria is an extremely rare, autosomal recessive, non-acute cutaneous porphyria, caused by uroporphyrinogen III synthase deficiency, codificated by UROS gene on the chromosome 10q26.2. Porphyrins deposit in cornea, bones and teeth. The first symptoms could be manifested in early childhood, with skin fragility, vesicles and bullae. Severe course produces acral tissues mutilation, eye involvement, hemolytic anemia and hypersplenism. The treatment is complex and it is based in the photoprotection. A correct diagnosis can significantly improve the quality and life expectancy of these patients. We present the case of a child with congenital erythropoietic porphyria confirmed by genetic analysis.

Clinicopathologic features of three cases of erythropoietic protoporphyria with liver involvement / 中华病理学杂志

Objective@#To investigate the clinicopathologic features of the erythropoietic protoporphyria (EPP) with liver involvement.@*Methods@#The clinical findings and hepatic biopsy of 3 cases of EPP diagnosed between July, 2011 to August, 2014 with liver involvement were reviewed, with relevant literature review.@*Results@#All patients presented with persistent and refractory abdominal pain, with obvious jaundice and deranged liver function. Imaging showed homogeneous hepatomegaly in all patients. Histologically, the hepatocytes were edematous, and contained numerous cytoplasmic globular brown pigments and bile pigments, which were also found in Kupffer cells, in the bile canaliculi and in some of dilated sinusoid. The pigments were of different sizes and showed uneven distribution. Some pigments showed bright red or yellow birefringence with a distinctive central maltese cross configuration on polarizing microscopy. Furthermore, some hepatocytes showed piecemeal necrosis and steatosis, the portal tracts were usually infiltrated by lymphocytes, with fibroplasia and biliary ductular reaction. There was no dilatation of intrahepatic bile ducts.@*Conclusion@#Full understanding of the clinical and pathological features of EPP with liver involvement can help to recognize this small group of patients, and to offer proper effective treatments.

Eritropoyetina como agente eritropoyético y no eritropoyético: consideraciones terapéuticas / Erythropoietic and non-erythropoietic functions of erythropoietin: therapeutic considerations / Eritropoietina como agente eritropoiético e não eritropoiético: considerações terapêuticas / Erythropoietic and non-erythropoietic functions of erythropoietin: therapeutic considerations

La producción de glóbulos rojos es controlada continuamente para suplir la desaparición de las células envejecidas y garantizar un aporte de oxígeno adecuado a todo el organismo. La citoquina pleitrópica eritropoyetina (Epo), originalmente definida por su rol en la eritropoyesis para prevenir la muerte programada de progenitores eritroides en la médula ósea, ha demostrado un rol antiapoptótico protector sobre diversos tejidos no hematopoyéticos. A la reconocida eficacia del tratamiento con eritropoyetina recombinante humana (rhuEpo) para contrarrestar la anemia que acompaña a patologías muy diversas, se agregan algunos aspectos que impiden lograr los resultados terapéuticos esperados, ya sea por resistencia al tratamiento o por el desarrollo de efectos adversos. Con el fin de prevenir estos efectos, así como reducir las dosis de rhuEpo en tratamientos crónicos se han desarrollado nuevos agentes que presentan modificaciones estructurales de la Epo, o bien alteraciones en las propiedades/actividad de la Epo nativa. Dado que, actualmente, los resultados sobre los efectos de la Epo sobre morbilidad/ mortalidad en diversas patologías no están suficientemente claros, nuevas investigaciones serán útiles para resolver dudas sobre la efectividad de la eritropoyetina y sus derivados o agentes alternativos con el fin de proveer bases sólidas para el desarrollo de ensayos clínicos concluyentes.

Erythropoietin (Epo), the cytokine required for promoting erythropoiesis through the proliferation and differentiation of erythroid cells, has been reported to act as a pleiotropic cytokine beyond the hematopoietic system. In contrast with the potentially beneficial effects attributed to recombinant human erythropoietin (rhuEpo), research has advanced to indicate that mortality and morbidity rates are increased in some patient groups when treated with rhuEpo. Some cardiac and systemic conditions may predispose to adverse events, and other factors, such as proinflammatory agents, may lead to resistance to erythropoietin treatment. Many compounds are currently under investigation in order to avoid these unwanted effects and to reduce the rhuEpo dose during chronic therapies. They are either erythropoiesis-stimulating agents different from erythropoietin or structurally modified erythropoietins with altered properties and activities. In recent reports, contrasting data have raised several concerns regarding the effectiveness of erythropoietin treatment to prevent adverse events. Therefore, much investigation is needed to provide a solid basis for the development of conclusive clinical trials.

A produção de glóbulos vermelhos é controlada continuamente para suprir o desaparecimento das células envelhecidas e garantir uma contribuição de oxigênio adequado a todo o organismo. A citocina pleiotrópica eritropoietina (Epo), originalmente definida por seu papel na eritropoiese para prevenir a morte programada de progenitores eritroides na medula óssea, tem demonstrado um papel anti-apoptótico protetor sobre diversos tecidos não hematopoiéticos. Adicionam-se à reconhecida eficácia do tratamento com eritropoietina recombinante humana (rhuEpo), para contra-arrestar a anemia que acompanha patologias muito diversas, alguns aspectos que impedem alcançar os resultados terapêuticos esperados, quer seja por resistência ao tratamento ou pelo desenvolvimento de efeitos adversos. Com o fim de prevenir estes efeitos, bem como reduzir as doses de rhuEpo em tratamentos crônicos foram desenvolvidos novos agentes que apresentam modificações estruturais da Epo, ou então alterações nas propriedades/atividade da Epo nativa. Devido a que, atualmente, os resultados sobre os efeitos da Epo sobre morbidade/mortalidade em diversas patologias não estão suficientemente claros, novas pesquisas serão úteis para resolver dúvidas sobre a efetividade da eritropoietina e seus derivados ou agentes alternativos visando a fornecer bases sólidas para o desenvolvimento de ensaios clínicos concludentes.

X-linked dominant protoporphyria:report of a pedigree and detection of ALAS2 gene mutations / 中华皮肤科杂志

Objective To report a pedigree with X?linked dominant protoporphyria(XLDPP), and to detect 5?aminolevulinic acid synthetase 2(ALAS2)gene mutations in this pedigree. Methods A clinical investigation was performed in a pedigree with XLDPP, and relevant data were collected from family members. A next?generation sequencing method was applied to screen possible mutation sites, and Sanger sequencing was performed to determine pathogenic gene mutations. Dermoscopy was conducted to observe skin lesions in the patients with XLDPP, and the Fotofinder system and very high frequency (VHF) ultrasound system were utilized to assess the severity of photodamage. Liver and gallbladder ultrasonography as well as blood examination were performed for all the family members. Results A deletion mutation, c.1706?1709ΔAGTG, was detected in the ALAS2 gene on the X chromosomes of all the patients in this family, which led to replacement or loss of 19-20 C?terminal residues through transcriptional frameshifting, and eventually caused an increase in ALAS2 activity. In the patients with XLDPP, skin photodamage was relatively severe;protoporphyrin?induced hepatobiliary damage was observed and aggravated with age;anemia and iron deficiency occurred sometimes. Conclusion The deletion mutation c.1706?1709ΔAGTG of the ALAS2 gene may be the underlying cause of XLDPP in this pedigree.

Erythropoietic Effects of Eremomastax polysperma Leaf Extracts on Female Prepubertal and Pubertal Wistar Rats.

This study assessed the erythropoietic effect of Eremomastax polysperma leaf extracts in female albino Wistar rats. Method: Twenty eight (28) female rats were divided into two major groups based on their weight and age. The duration of administration of E. polysperma extracts lasted for twenty one (21) days. This study was carried out in the Department of Biochemistry University of Calabar, between February and March 2013. A significant increase (P<0.05) in red blood cell count (RBC) (8.17±0.48, 6.46±0.37) and Haemoglobin (Hb) count (15.13±1.03, 13.27±0.7) was observed in the prepubertal group compared to the control, while packed cell volume (PCV) was significantly increased (P<0.05) in the pubertal group compared to the control (55.40±4.40, 48.63±2.33 respectively). This suggests that E. polysperma leaf extract can be used as a haematinic and a therapy for anaemic conditions.

Aspectos patognomônicos da doença de Günther / Pathognomonic aspects of Günther?s disease

A doença de Günther ou porfiria eritropoiética congênita é uma desordem autossômica recessiva. Causada por um defeito na enzima uroporfirinogênio III sintase, leva a um acúmulo de isômeros não fisiológicos e patogênicos da porfirina. As manifestações clínicas da doença incluem eritrodontia, hipertricose, fragilidade óssea, complicações oculares, anemia hemolítica e fotossensibilidade extrema. Apesar da escassa literatura científica atualizada sobre a doença de Günther, realizou-se esta revisão bibliográfica com a finalidade de descrever pontos importantes da etiologia, diagnóstico, prognóstico, tratamento e prevenção dessa patologia. Foram consultadas as bases de dados Pubmed, Lilacs e SciELO determinando as buscas pelas palavras-chaves: porfiria eritropoiética, porfirias, porfiria cutânea tardia, porfiria variegata, porfiria hepatoeritropoiética e erros inatos do metabolismo. Pacientes com a doença de Günther podem apresentar as piores manifestações cutâneas de todas as porfirias, isso se dá devido ao aumento de porfirinas lipossolúveis que se depositam na pele. Na idade adulta os pacientes podem desenvolver osteólise severa, ressorção de falanges terminais, contraturas e outras deformidades. A deficiência de vitamina D, decorrente da não exposição ao sol, pode contribuir para tais anormalidades na estrutura do osso. Manifestações oculares incluem conjuntivite, blefarite, fotofobia, cataratas, perda de cílios e sobrancelhas e cicatriz na córnea, o que pode levar à cegueira. A doença de Günther apresenta uma variabilidade clínica considerável. Embora os tratamentos disponíveis sejam limitados, o prognóstico nem sempre é desfavorável.

Liver transplantation for acute-on-chronic liver failure from erythropoietic protoporphyria

Erythropoietic protoporphyria (EPP) is an inherited disorder of the heme metabolic pathway that is characterized by accumulation of protoporphyrin in the blood, erythrocytes, and tissues, and cutaneous manifestations of photosensitivity, all resulting from abnormalities in ferrochelatase (FECH) activity due to mutations in the FECH gene. Protoporphyrin is excreted by the liver, and excess protoporphyrin leads to cholelithiasis with obstructive episodes and chronic liver disease, finally progressing to liver cirrhosis. Patients with end-stage EPP-associated liver disease require liver transplantation. We describe here a 31-year-old male patient with EPP who experienced acute-on-chronic liver failure and underwent deceased-donor liver transplantation. Surgical and postoperative care included specific shielding from exposure to ultraviolet radiation to prevent photosensitivity-associated adverse effects. The patient recovered uneventfully and was doing well 24 months after transplantation. Future prevention and treatment of liver disease are discussed in detail.

Effect of intracerebrovascular injection of ghrelin on some of erythropoietic indicators in 42-day-old broiler chicken

Objective: To evaluate the erythropoietic indicators in 42-day-old broiler chicks following intracerebrovascular injection of exogenous rat ghrelin at 21 day of age. Methods: A total of 90 male chicks were divided into three experimental groups including three replicates (10 chicks for each replicate): group 1 without any ghrelin injection, group 2 subjected to intracerebrovascular injection of 0.5 mg ghrelin/kg b.w. and group 3 subjected to intracerebrovascular injection of 1.0 mg ghrelin/kg b.w. at 21 days of age. Results: Intracerebrovascular injection of 0.5 or 1.0 mg ghrelin/kg b.w. at 21 days of age did not have any significant effect on the measured erythropoietic indicators including red blood cell, hematocrit, haemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. Conclusions:Intracerebrovascular injection of exogenous rat ghrelin does not have any considerable effect on erythropoietic activity of broiler chickens.

Congenital erythropoietic porphyria with two mutations of the uroporphyrinogen III synthase gene (Cys73Arg, Thr228Met).

Congenital erythropoietic porphyria (CEP) is an autosomal recessive inborn error of metabolism that results from the markedly deficient activity of uroporphyrinogen III synthase (UROS). We describe a 14-year-old girl with red urine since infancy, progressive blistering and scarring of the skin, and moderate hemolytic anemia. After years of skin damage, her face is mutilated; she has a bald patch on the scalp, hypertrichosis of the neck, areas of skin darkening, and limited joint movements of the hands. Total urine excretion and fecal total porphyrin were both markedly raised above normal levels. Sequencing of the UROS gene identified two mutations causing CEP (Cys73Arg, Thr228Met). The patient lesions are progressing. Bone marrow transplantation and/or gene therapy are proposed as the next steps in her treatment. In brief, we describe a CEP with confirmed two pathogenic mutations, severe phenotype and discuss the various treatment options available.

Mutation analysis of ferrochelatase gene in a pedigree with erythropoietic protoporphyria / 中华皮肤科杂志

Objective To characterize the inheritance of erythropoietic protoporphyria (EPP) by detecting the mutations of ferroehelatase (FECH) gene in a Chinese family with EPP. Methods Peripheral blood samples were obtained from 4 patients and 3 unaffected individuals in a family with EPP, as well as from 50 unrelated healthy human controls. PCR was performed to amplify all the 11 exons and flanking sequence of FECH gene followed by direct sequencing. Results A splicing mutation,I.e., IVS3+1G→A, was identified in the proband as well as his symptomatic sister, cousin, grandfather and asymptomatic mother, but not in his asymptomatic father, grandmother, or unrelated healthy controls. The genotypes IVS1-23 T/C and IVS3-48 C/T were noted in the proband, his father, sister, cousin and grandfather, but absent in his mother or grandmother who carried IVS1-23 C/C and IVS3-48 T/T genotypes. Conclusions A novel splicing mutation is found in the FECH gene in a Chinese EPP family, which, together with two lowly expressed alleles IVS1-23T and IVS3-48C, is likely to be responsible for the clinical phenotype of EPP in this family.

Cholestyramine resin for erythropoietic protoporphyria with severe hepatic disease: a case report / 대한간학회지

Erythropoietic protoporphyria (EPP) is a rare disorder of heme biosynthesis caused by mutations in the gene encoding the enzyme ferrochelatase. In EPP, deficient ferrochelatase activity leads to the excessive production and biliary excretion of protoporphyrin (PP). The major clinical features of EPP are photosensitivity and hepatobiliary disease that may progress to severe liver disease, that are caused by the toxicity of PP. EPP-related liver disease has been treated medically or surgically including liver transplantation. We described a 20-year-old male with severe liver disease who was diagnosed with EPP based on clinical and laboratory findings. He was treated with cholestyramine resin. Six months after the treatment, he was doing well without any abdominal pain or photosensitivity.

FECH gene mutation in a Chinese family with erythropoietic protoporphyria / 中华皮肤科杂志

Objective To investigate the FECH gene mutation in a Chinese family with erythropoietic protoporphyria, to explore the relationship between gene mutation and clinical manifestations so as to estab-lish a basis for the genetic diagnosis and treatment of erythropoietic protoporphyria. Methods Clinical data on a Chinese family with typical EPP was collected. Peripheral blood was obtained from patients, unaffected individuals in the family and 50 unrelated human controls. Genomic DNA was extracted and PCR was per-formed to amplify the whole coding regions (exons 1 to 11) of FECH gene and their flanking intron sequences followed by direct sequencing to detect possible mutations. Results Based on clinical symptom and por-phyrin levels, a diagnosis of erythropoietic protoporphyria was made in 3 family members. DNA fragments of expected size were amplified by PCR. Gene sequencing revealed a heterozygons mutation (IVS1 + 1G >C) in intron 1 of FECH gene in the proband, his sister and father, but not in unaffected family members or unrelated human controls. Also, an IVS1-23C/T polymorphism associated with low expression alleles was observed in intron 1 of FECH gene of the proband, his sister and mother. Conclusions A novel mutation in the donor splice site of intron 1 of FECH gene is first reported in a Chinese family with EPP; this muta-tion may lead to a deficiency of FECH gene and serve as a molecular basis of development of erythropoietic protoporphyria.

Ocular Manifestation of Compound Heterozygotic Mutation in Congenital Erythropoietic Porphyria

PURPOSE: Congenital erythropoietic porphyria (CEP) is a rare disorder inherited as an autosomal recessive trait, which is characterized by almost complete reduction of uroporphyrinogen III synthase (UROS) activity. The authors of the present study report a case of congenital erythropoietic porphyria with severe ocular involvement. CASE SUMMARY: A 27-year-old male patient diagnosed with congenital erythropoietic porphyria was referred to our clinic with a history of ocular pain, and foreign body sensation in both eyes. Visual acuity was light perception in both eyes. Severe scarring of eyelids, corneal leukoma with neovascularization, total limbal deficiency and scleromalacia were observed in both eyes. Identification of the uroporphyrinogen III synthase (UROS) gene mutation revealed the patient had a compound heterozygote mutation at p.Q249X (c.745C>T) and p.L237P (c.710T>C) in exon 10. CONCLUSIONS: CEP is clinically characterized by severe cutaneous photosensitivity, hemolytic anemia and porphyriuria. In addition to these manifestations, the authors report a severe ocular involvement in a patient with CEP who had a compound heterozygote mutation at p.Q249X (c.745C>T) and p.L237P (c.710T>C) in exon 10.